These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30324343)

  • 1. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
    Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.
    Walter T; Horgan AM; McNamara M; McKeever L; Min T; Hedley D; Serra S; Krzyzanowska MK; Chen E; Mackay H; Feld R; Moore M; Knox JJ
    Eur J Cancer; 2013 Jan; 49(2):329-35. PubMed ID: 22947649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer.
    Kang EJ; Choi YJ; Kim JS; Park KH; Oh SC; Seo JH; Kim HJ; Kang KW; Yu ES; Shin SW; Kim YH; Kim JS
    Chemotherapy; 2014; 60(2):91-98. PubMed ID: 25720697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review.
    Brungs D; Aghmesheh M; Sjoquist K; Goldstein D
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e291-e297. PubMed ID: 27860270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
    Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
    J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
    Jung JH; Lee HS; Jo JH; Cho IR; Chung MJ; Bang S; Park SW; Song SY; Park JY
    Chemotherapy; 2017; 62(6):361-366. PubMed ID: 28848173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age and comorbidity in advanced or recurrent biliary tract cancer receiving palliative chemotherapy.
    Takahara N; Nakai Y; Saito K; Sasaki T; Suzuki Y; Inokuma A; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Isayama H; Koike K
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1828-1835. PubMed ID: 32267557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.
    Motoyama H; Kobayashi A; Yokoyama T; Shimizu A; Kitagawa N; Notake T; Fukushima K; Masuo H; Yoshizawa T; Miyagawa SI
    World J Surg; 2017 Nov; 41(11):2817-2829. PubMed ID: 28717913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Itraconazole After First-line Chemotherapy on Survival of Patients with Metastatic Biliary Tract Cancer.
    Tsubamoto H; Sonoda T; Ikuta S; Tani S; Inoue K; Yamanaka N
    Anticancer Res; 2015 Sep; 35(9):4923-7. PubMed ID: 26254389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
    Filippi R; Leone F; Fornaro L; Aprile G; Casadei-Gardini A; Silvestris N; Palloni A; Satolli MA; Scartozzi M; Russano M; Lutrino SE; Lombardi P; Frega G; Garattini SK; Vivaldi C; Spadi R; Giulia O; Fenocchio E; Brunetti O; Aglietta M; Brandi G
    J Chemother; 2022 Apr; 34(2):123-132. PubMed ID: 34313188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer.
    Nakai Y; Isayama H; Sasaki T; Takahara N; Saito K; Takeda T; Umefune G; Saito T; Takagi K; Watanabe T; Hamada T; Uchino R; Mizuno S; Yamamoto K; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
    Anticancer Res; 2016 Sep; 36(9):4965-70. PubMed ID: 27630357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer.
    Jo J; Kwon HW; Park S; Oh DY; Cheon GJ; Bang YJ
    J Nucl Med; 2017 Aug; 58(8):1255-1261. PubMed ID: 28254865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
    Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
    Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer.
    Il Yu J; Chul Park H; Hoon Lim D; Oh Park J; Suk Park Y; Tae Kim S; Ho Choi S; Wook Choi D; Woong Han I; Seok Heo J
    Tumori; 2017 Jul; 103(4):345-352. PubMed ID: 28708225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-1 monotherapy in patients with advanced biliary tract cancer.
    Sasaki T; Isayama H; Yashima Y; Yagioka H; Kogure H; Arizumi T; Togawa O; Matsubara S; Ito Y; Nakai Y; Sasahira N; Hirano K; Tsujino T; Tada M; Kawabe T; Omata M
    Oncology; 2009; 77(1):71-4. PubMed ID: 19556812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.